PhRMA ships benefit-risk program to U.K. center

The Pharmaceutical Research and Manufacturers of America transferred the development of its benefit-risk assessment program to the U.K.'s Centre for Innovation in Regulatory Science Ltd. CIRS will incorporate PhRMA's program -- known as the Benefit-Risk Action Team (BRAT) framework -- into its Unified Methodologies for Benefit-Risk Assessment (UMBRA) initiative for documenting decision making in benefit-risk assessments of medicines. ...